
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
G-CSF CRISPR Activation Plasmid (h) | sc-400936-ACT | 20 µg | $397.00 | |||
G-CSF CRISPR Activation Plasmid (h2) | sc-400936-ACT-2 | 20 µg | $397.00 |
CSF3 encodes human granulocyte colony-stimulating factor (G-CSF), a secreted cytokine that regulates neutrophil lineage commitment, proliferation, and mobilization from the bone marrow. G-CSF signals through CSF3R to activate JAK/STAT, MAPK/ERK, and PI3K/AKT pathways, shaping granulopoiesis, innate immune readiness, and inflammatory responses. Dysregulated CSF3–CSF3R signaling is linked to altered neutrophil dynamics and myeloid cell behavior in inflammatory disorders and hematologic malignancy contexts. As a tractable cytokine axis, CSF3 is widely used to interrogate cytokine-driven transcriptional programs and myeloid differentiation states.
G-CSF CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous CSF3 expression without altering the underlying DNA sequence.
G-CSF CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the CSF3 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the CSF3 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous G-CSF expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native CSF3 locus and enabling the study of G-CSF-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of G-CSF pathway restoration in tumor cells with silenced or reduced CSF3 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.